Elanco(ELAN)

Search documents
Elanco Announces Credelio Quattro Moves to Final FDA Administrative Review
Prnewswire· 2024-08-20 10:27
Product Development and Approval - The company's broad-spectrum parasiticide, Credelio Quattro, is on track for U.S. FDA approval in October 2024, with a targeted launch in the first quarter of 2025 [1] - The FDA has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway [1] - Credelio Quattro is expected to be positively differentiated, with approval sought for indications providing the broadest parasite coverage, including fleas, ticks, heartworms, and other internal parasites like tapeworm [2] - The company is finalizing the manufacturing scale-up to optimize the launch of Credelio Quattro [2] Innovation and Pipeline - The company expects to launch a potential blockbuster product each of the next three quarters in large, fast-growing, or new markets, contributing significantly to its revenue [2] - The company anticipates $600 million to $700 million in innovation sales for 2025 [2] - The company has two potential blockbuster products, Zenrelia and Credelio Quattro, in the final administrative review at the FDA, showcasing its R&D organization's high capacity and ability to deliver consistent high-impact innovation [3] - The company completed the Bovaer review ahead of schedule, further demonstrating its innovation capabilities [3] Company Overview - Elanco Animal Health is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets [4] - The company has nearly 70 years of animal health heritage and is committed to improving the health of animals, creating value for farmers, pet owners, veterinarians, and society as a whole [4] - Elanco's vision is "Food and Companionship Enriching Life," and it is driven by its Elanco Healthy Purpose™ sustainability pillars to advance the health of animals, people, the planet, and the enterprise [4] FDA Approval Process - The FDA's Center for Veterinary Medicine (CVM) approves and regulates new animal drugs, with the approval process including up to five major technical sections and two minor technical sections [3] - Once all technical sections are complete, the drug sponsor submits the New Animal Drug Application (NADA) for the final administrative review [3]
ELAN INVESTMENT NOTICE: Did Elanco Commit Securities Fraud? Investors that Lost Money are Encouraged to Contact BFA Law about its Investigation (NYSE: ELAN)
GlobeNewswire News Room· 2024-08-18 10:17
NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
Elanco Animal Health: Positioned For Success
Seeking Alpha· 2024-08-16 13:25
Monty Rakusen Background In business since 1954 as a division of Eli Lilly (LLY), Elanco Animal Health (NYSE:EL.AN) was spun off as an independent public company in 2018. In the animal health space, Elanco is second by revenue, behind leader Zoetis (ZTS), with roughly half the revenue of Zoctis, Zoetis was spun off from Pfizer in 2012. Jeffrey N. Simmons has been President and CEO of Elanco since the spinoff from Eli Lilly. On August 1, 2020, Elanco purchased Bayer Animal Health in a deal valued at $6.99 bi ...
ELAN INVESTIGATION NOTICE: Elanco Investors are Notified to Contact BFA Law about its Investigation of the Company for Violations of the Federal Securities Laws (NYSE:ELAN)
GlobeNewswire News Room· 2024-08-16 10:19
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)
Prnewswire· 2024-08-15 12:27
Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours and sustains that advantage throughout the dosing interval.1,2,3 According to the ...
ELAN FRAUD ALERT: BFA Law is Investigating Elanco for Securities Fraud – Contact the Firm if You Suffered Losses on Your Investment (NYSE:ELAN)
GlobeNewswire News Room· 2024-08-14 11:29
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
ELAN INVESTOR NEWS: Elanco Investors that Suffered Losses are Encouraged to Contact BFA Law about a Potential Class Action Lawsuit for Securities Fraud (NYSE:ELAN)
GlobeNewswire News Room· 2024-08-12 10:13
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
ELAN INVESTOR ALERT: A Securities Fraud Investigation was Initiated Against Elanco (NYSE:ELAN); Investors that Lost Money are Encouraged to Contact BFA Law
GlobeNewswire News Room· 2024-08-10 11:38
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
Elanco(ELAN) - 2024 Q2 - Earnings Call Transcript
2024-08-08 16:31
Elanco Animal Health (NYSE:ELAN) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeffrey Simmons - President & Chief Executive Officer Todd Young - Executive Vice President & Chief Financial Officer Conference Call Participants Jon Block - Stifel Michael Ryskin - Bank of America Umer Raffat - Evercore ISI Chris Schott - JPMorgan Erin Wright - Morgan Stanley Brandon Vazquez - William Blair Balaji Prasad - Barclays David Westenberg - Pi ...
Elanco Animal Health (ELAN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2024-08-08 14:35
Elanco Animal Health Incorporated (ELAN) reported $1.18 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 12%. EPS of $0.30 for the same period compares to $0.18 a year ago. The reported revenue represents a surprise of +3.23% over the Zacks Consensus Estimate of $1.15 billion. With the consensus EPS estimate being $0.24, the EPS surprise was +25.00%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...